Application of toxicogenomics to drug development

Expert Review of Molecular Diagnostics

Volumn 2, Issue 4, 2002, Pages 337-345

  Lakkis, Maha M ^a   DeCristofaro, Marc F ^a   Ahr, Hans J ^a   Mansfield, Traci A ^a  

^a CURAGEN CORPORATION   (United States)

Author keywords

Drug development; Expression data analysis; Gene expression profiling; Toxicogenomics; Toxity screen

Indexed keywords

DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; GENOMICS; MOLECULAR GENETICS; REVIEW; TOXICOGENOMICS; DRUG DESIGN; FORECASTING; GENE EXPRESSION PROFILING; GENETIC MARKER; INSTRUMENTATION; METHODOLOGY; PHARMACOGENETICS;

DRUG DESIGN; FORECASTING; GENE EXPRESSION PROFILING; GENETIC MARKERS; PHARMACOGENETICS;

EID: 0036020075     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.4.337     Document Type: Review

References (63)

1. The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes
2. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
3. Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal Type 1 and Type 2 cytokine-mediated inflammatory reactions
4. Microarray analysis of Drosophila development during metamorphosis
5. Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray
6. Genome-wide gene expression profiles of the developing mouse hippocampus
7. Gene expression changes associated with cytotoxicity identified using cDNA arrays
8. Expression profiling of acetaminophen liver toxicity in mice using microarray technology
9. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver
10. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles
11. Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles
12. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity
13. Cluster analysis and display of genome-wide expression patterns
14. Gene expression analysis by transcript profiling coupled to a gene database query
15. Gene profiling techniques and their application in angiogenesis and vascular development
16. Identification of toxicologically predictive gene sets using cDNA microarrays
17. RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays
18. Application of genomics to the definition of the molecular basis for toxicity
19. Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells
20. Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays
21. Microarrays and toxicology: The advent of toxicogenomics
22. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology
23. Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation
24. Mechanisms of hepatotoxicity
25. Recent advances in molecular mechanisms of nephrotoxicity
26. Drug-induced nephrotoxicity
27. Clinical toxicology of cardiovascular drugs
28. Test systems to identify reproductive toxicants
29. Reproductive toxicology: The science today
30. Role of the lung in accumulation and metabolism of xenobiotic compounds - Implications for chemically induced toxicity
31. The role of metabolism in chemical-induced pulmonary toxicity
32. Biochemical markers of neurotoxicity. A review of mechanistic studies and applications
33. Gene imprinting in developmental toxicology: A possible interface between physiology and pathology
34. Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity
35. Open systems: Panoramic views of gene expression
36. The impact of genomics-based technologies on drug safety evaluation
37. Navigating gene expression using microarrays - A technology review
38. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
39. Serial analysis of gene expression
40. Gene expression data analysis
41. Basic microarray analysis: Grouping and feature reduction
42. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
43. Analysis of large-scale gene expression data
44. Analysis of gene expression data using self-organizing maps
45. Making the most of microarray data
46. Gene expression profiling predicts clinical outcome of breast cancer
47. Knowledge-based analysis of microarray gene expression data by using support vector machines
48. Machine learning of functional class from phenotype data
49. Gene selection for sample classification based on gene expression data: Study of sensitivity to choice of parameters of the GA/KNN method
50. Finding genes in the C2C12 osteogenic pathway by k-nearest-neighbor classification of expression data
51. A novel method of protein secondary structure prediction with high segment overlap measure: Support vector machine approach
52. Classifying G-protein coupled receptors with support vector machines
53. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals
54. Inter-species differences in drug properties
55. Toxicogenomics and drug discovery: Will new technologies help us produce better drugs?
56. Toxicoproteomics - A new preclinical tool
57. Toxicology and genetic toxicology in the new era of 'toxicogenomics': Impact of '-omics' technologies
58. Pharmaceutical proteomics
59. Key challenges for toxicologists in the 21st century
60. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data
61. Metabonomic characterization of genetic variations in toxicological and metabolic responses using probabilistic neural networks
62. Safety assessment of new products developed by the pharmaceutical industry
63. Metabonomic applications in toxicity screening and disease diagnosis